ClinicalTrials.gg
RecruitingNCT07586709Updated Oct 2, 2026

In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

An Early Phase 1 interventional study of In vivo BCMA/GPRC5D Tandem Dual CAR-T cell in Plasma Cell Neoplasms, sponsored by Liping Dou. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Liping Dou · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 2, 2026Now RecruitingFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Neoplasms, Plasma Cell with a site in China — 20 open to participants now, 21 under way, 1 of them phase 3. Neoplasms, Plasma Cell · China.

Planned enrollment
21st of 28
18 · median 20
Started
2026
with 5 others
Phase 1
10 of 32
7 open now
Primary completion
2029-03
later than 20 of 20 live
Registered
30th of 32
by date

Among the 32 studies in Neoplasms, Plasma Cell with a site in China, this one is the 21st largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 20 of the 20 other live ones, and was the 30th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

20 of the 32 studies in Neoplasms, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Neoplasms, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.

Read the detailed description

This is a single-center, open-label, single-arm, prospective study designed to evaluate the safety of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms. The study employs a dose-escalation design to assess safety, tolerability, and preliminary efficacy. Safety assessments primarily focus on potential adverse events (AEs) following infusion of SL4903 injection, including the number of cases, incidence rates, and severity of cytokine release syndrome, immune effector cell therapy-related neurotoxicity, hematologic toxicity, organ toxicity, ect. Efficacy assessments will include overall objective response rate (ORR), event-free survival (EFS), overall survival (OS), progression-free survival (PFS), duration of complete remission, relapse rate, and mortality rate. Exploratory analyses will focus on characterizing the in vivo kinetics of CAR-T cells and the clonal evolution of plasma cell neoplasms during and after consolidation treatment.

03

Conditions studied

  • Plasma Cell Neoplasms

Keywords

  • in vivo CAR-T Cell Therapy
  • BCMA
  • GPRC5D
  • plasma cell neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of by the subject or legally authorized representative, with willingness and ability to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.
  • Diagnosis of plasma cell neoplasms meeting the following criteria:

    1. Clonal plasma cells confirmed to be BCMA and/or GPRC5D positive by flow cytometry or immunohistochemistry;
    2. Previously treated with at least 2 lines of anti-plasma cell neoplasms therapy, with at least 1 complete treatment cycle for each line, and evidence of disease progression within 12 months after the most recent anti-plasma cell neoplasms treatment, or being refractory to both immunomodulatory drugs and proteasome inhibitors, with disease progression within 2 months after the most recent anti-plasma cell neoplasms treatment (according to the IMWG diagnostic criteria)
  • Age 18 to 75 years (inclusive), male or female.
  • (ECOG) performance status of 0 to 2.
  • > 3 months from the date of informed consent.
  • (HGB) ≥ 60 g/L (transfusion allowed).
  • Adequate organ function (hepatic, renal, cardiac, and pulmonary):

    1. Creatinine ≤ 2 × ;
    2. (LVEF) ≥ 50%;
    3. Oxygen saturation > 90%;
    4. Total ≤ 1.5 × ULN; and AST ≤ 2.5 × ULN.
  • Willingness to use highly effective from signing of informed consent until 1 year after SL4903 infusion.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac dysfunction with (LVEF) \< 50%.
  • History of severe pulmonary impairment.
  • Concurrent diagnosis of another active .
  • Uncontrolled active infection.
  • History of severe disease or primary immunodeficiency.
  • Active hepatitis (defined as or above the lower limit of detection).
  • (HIV) infection or acquired immunodeficiency syndrome (AIDS), or active syphilis.
  • History of severe to biological products (including antibiotics).
  • hematopoietic stem cell transplant recipients with ongoing acute (GVHD) despite discontinuation of therapy for at least one month prior to screening.
  • Any other severe comorbidities or laboratory abnormalities that, in the investigator's opinion, would increase the risk to the subject or interfere with study results, rendering the subject unsuitable for participation.
  • Pregnant or breastfeeding women (including women of who are pregnant or lactating).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    In vivo BCMA/GPRC5D Tandem Dual CAR-T

    Participants receive treatment of In vivo BCMA/GPRC5D Tandem Dual CAR-T cell following a 3+3 dose-escalation design.

    Drug: In vivo BCMA/GPRC5D Tandem Dual CAR-T cell

Interventions

  • DrugIn vivo BCMA/GPRC5D Tandem Dual CAR-T cell

    Administration of in vivo BCMA/GPRC5D tandem dual CAR-T cells. Three dose levels (dose A, dose B, dose C) will be evaluated using a standard 3+3 dose-escalation design.

    Also known as: SL4903

06

What researchers measure

Primary outcomes

  1. Number and incidence rate with Each Grade of Cytokine Release Syndrome (CRS)

    CRS severity will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading. The grade ranges from 1 to 4, where a higher grade indicates a worse outcome.

    Time frame: 1 month after treatment

  2. Dose-limiting toxicities (DLTs)

    Dose limiting toxicity will be assessed after injection

    Time frame: 1 month after treatment

  3. Number and incidence rate of Each Grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    ICANS severity is graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading, which incorporates the Immune Effector Cell-Associated Encephalopathy (ICE) assessment. The ICE score ranges from 0 to 10, with higher scores indicating better cognitive function. ICANS grade ranges from 1 to 4, where a higher grade indicates a worse outcome.

    Time frame: 1 month after treatment

  4. Number and incidence rate of Treatment-Associated Adverse Events (AEs)

    All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

    Time frame: 1 years after treatment

Secondary outcomes

  1. Overall Objective Response Rate (ORR)

    Overall objective response rate (ORR) refers the sum of the proportions of complete remission (CR) and partial remission (PR).

    Time frame: Day 14, Day 28, Month 2 , Month 3, Month 6, Month 9, Month 12, Month 18, Month24 after the treatment

  2. overall survival (OS)

    Overall survival (OS) refers to the time from the start of treatment to the death of the patient for any reason.

    Time frame: 2 years after treatment

  3. progression free survival (PFS)

    Progression free survival (PFS) refers to the time from treatment to the first disease progression or death of the patient for any reason.

    Time frame: 2 years after treatment

  4. duration of response (DOR)

    Duration of Response (DOR) refers to the time from the first assessment of plasma cell neoplasms as a complete or partial response to the first assessment of PD (Progressive Disease) or death from any cause.

    Time frame: 2 years after treatment

  5. time to progression (TTP)

    Time to progression (TTP) refers to the time from treatment to the first plasma cell neoplasms progression.

    Time frame: 2 years after treatment

  6. recurrence rate

    The recurrence rate refers to the proportion of patients with plasma cell neoplasms recurrence after treatment.

    Time frame: 2 years after treatment

  7. Cmax of CAR-T Cells

    CAR-T kinetics would be detected by flow cytometry or qPCR in peripheral blood or bone marrow at each important time points. Cmax is the peak expansion value of CAR-T cells. Cmax is the peak expansion value of CAR-T cells.

    Time frame: 1 month after treatment

  8. Tmax of CAR-T Cells

    CAR-T kinetics would be detected by flow cytometry or qPCR in peripheral blood bone marrow at each important time points. Tmax is the time of the occurrence of expansion peak.

    Time frame: 1 month after treatment

  9. AUC(0-28d)

    AUC(0-28d) is the area under the peripheral blood CAR-T cell concentration versus time curve calculated from the time of treatment to 28 days post-treatment, using the linear trapezoidal method.

    Time frame: 1 month after treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2029, 34 months after the start.

Of 35 non-industry phase 1 interventional studies under Neoplasms, Plasma Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 96. This study's planned 34 months is below that.

Counting every sponsor, half of 51 studies reached it within 61 months; a quarter within 27 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 14, 2026
StartActual
May 9, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added — first site in China
Show site
  • Chinese PLA General Hospital · Beijing, China
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Chinese PLA General Hospital · Beijing, China
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07586709
Lead sponsor
Liping Dou
Responsible party
Liping Dou (Director, Chinese PLA General Hospital) — Sponsor-investigator
First posted
May 14, 2026
Start date
May 9, 2026
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Yu ZHAO
Contact
zhaoyu301@126.com
13601051848
Liping DOU
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion